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Background: Even though osteoarthritis (OA) is the most common musculoskeletal dysfunction, there are no
effective pharmacological treatments to treat OA due to lack of understanding in OA pathology. To better
understand the mechanism in OA pathogenesis and investigate its effective target, we analyzed miRNA profiles
during OA pathogenesis and verify the role and its functional targets of miR-488.
Results: Human articular chondrocytes were obtained from cartilage of OA patients undergoing knee replacement
surgery and biopsy samples of normal cartilage and the expression profile of miRNA was analyzed. From expression
profile, most potent miR was selected and its target and functional role in OA pathogenesis were investigated
using target validation system and OA animal model system. Among miRNAs tested, miR-488 was significantly
decreased in OA chondrocytes Furthermore, we found that exposure of IL-1β was also suppressed whereas
exposure of TGF-β3 induced the induction of miR-488 in human articular chondrocytes isolated from biopsy
samples of normal cartilages. Target validation study showed that miR-488 targets ZIP8 and suppression of ZIP8 in
OA animal model showed the reduced cartilage degradation. Target validation study showed that miR-488 targets
ZIP8 and suppression of ZIP8 in OA animal model showed the reduced cartilage degradation.
Conclusions: miR-488 acts as a positive role for chondrocyte differentiation/cartilage development by inhibiting
MMP-13 activity through targeting ZIP-8.
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Osteoarthritis (OA) is the most common musculoskel-
etal disorder and the most prevalent articular pathology
induced by multiple factors such as obesity, anatomic
abnormalities, joint instability, and joint injury [1,2]. OA
is characterized by degradation of extracellular matrix
macromolecules and decreased expression of chondro-
cyte protein and resulted severe joint pain, loss of move-
ment, and progressive irreversible dysfunction [3,4].
Epidemiological studies showed that many factors in-
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reproduction in any medium, provided the orcould contribute OA pathology directly or indirectly [5,6].
Currently, there are no effective pharmacological treat-
ments to treat OA although some drugs reduce symptoms
and slow the progression of OA. Further investigation and
understanding of OA pathology is needed and important
to develop effective therapeutic targets to control OA.
MicroRNAs (miRNA) are single-stranded RNA of 18–
24 nucleotides generated by sequential processing of long
RNA transcripts by two key RNase III proteins, Drosha
and Dicer [7]. They bind to 3’ untranslated region of target
messenger RNAs and either cleavage the mRNAs or re-
press translation depending on perfect pairing/imperfect
pairing [8,9]. Although some algorithms are used to pre-
dict potential mRNA targets, only a few miRNAs have
been validated and assigned to specific mRNAs. A select
number of miRNAs have been shown to play key roles in
diverse regulatory pathways, including control of de-
velopment [10,11], cell proliferation/differentiation [12,13]td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[14,15]. Studies on Dicer-null mice showed a greatly de-
creased chondrocyte proliferation and accelerated hyper-
trophy leading to severe growth defects and premature
death of mice indicating the important role of miRNAs in
cartilage function [16]. A specific miRNA has been noted
not only as key molecules in intracellular regulatory net-
works, but also as biomarkers for various pathological
conditions [17]. Recently, specific miRNAs were reported
to be involved in chondrogenesis and inflammatory cartil-
age diseases [18,19]. MiR-675 regulates type II collagen in
articular chondrocytes [20], miR-18 regulates chodnrocytic
phenotype by targeting Ccn2/Ctgf [21]. Despite consider-
able evidences regarding the involvement of miRNAs in
cartilage development [22,23], identifications and func-
tions of miRNAs in cartilage development/degeneration
are poorly understood.
In the present study, to better understand the molecu-
lar mechanisms involved in the OA pathology, we iden-
tify miRNAs from normal and OA chondrocytes and
characterize the functional role of miRNA-488, which
could have important diagnostic and therapeutic potential.
Methods
Primary cultures of human chondrocytes
Human chondrocytes were prepared from macroscopic-
ally severely damaged zones of osteoarthritic knee joints
obtained undergoing total knee replacement or biopsy of
normal cartilages. The study was carried out in full ac-
cordance with Wonkwang University ethics guidelines
and cartilage samples were collected after obtaining writ-
ten informed consent of the donors. Cartilage small slices
were sequentially digested with 0.06% collagenase (Sigma)
then seeded at a density of 1.5 × 104 cells/cm2 in culture
medium consisting of DMEM (Gibco-Invitrogen) supple-
mented with 10% fetal bovine serum (FBS), 100 IU/ml
penicillin, and 100 μg/ml streptomycin (Gibco-Invitrogen).
Real-time quantitative reverse transcription-polymerase
chain reaction (RT-PCR)
The PCR program consisted of an initial denaturation
step at 95 °C for 10 min, followed by 40 cycles of 10 sec at
95 °C, 15 sec at 60 °C and 17 sec at 72 °C using to amplify
human type II collagen (5’-tgtacgtgaacctgctattgccct-3’ and
5’-taccacgtgcatgtgaaagggact-3’), human MMP-13 (5′-ttgcag
agcgctacctgagatcat-3′ and 5′-tttgccagt cacctctaagccgaa-3′)
human ZIP1 (5’-gctaaccatg aaggctcagctt-3’ and 5’-ccccgcg
aaacagcttacta-3’), human ZIP2 (5’- catcaccg gctagtcctcaga-
3’ and 5’-aaccctgctcccaggaaaac-3’), human ZIP3 (5’-tccctgct
ccccgtgaa-3’ and 5’-cgagcgatgggccttct-3’), human ZIP4 (5’-
gtgtgtgggacacggtatgc-3’ and 5’-tgttccgacagtccata tgca-3’),
human ZIP6 (5’-g caggctgtcctttataatgca-3’ and 5’-aattcctg
ttgccattccaaga-3’), human ZIP7 (5’-ctacttcagatcttgctc agtt
ttgc-3’ and 5’-tgaggtg caggaaagcatctc-3’), human ZIP8 (5’-gatcggcccaagcacaaa-3’ and 5’- acaggaatccatatccccaaact-3’),
human ZIP9 (5’-tggcttagagcggaatcga-3’ and 5’- ggtgctgcc
aatgca aaga-3’), human ZIP10 (5’-caccacggcgagaacaaaa-3’
and 5’- cttgtggtgccactggtgat-3’), human ZIP12 (5’-agcagaa
gccgtgggagtt-3’ and 5’- tggtcaccagcagagagaacct-3’), using
monitoring SYBR Green I. To normalize the output, the
expression of each gene of interest was divided by GAPDH
gene (5'-gatcatcagcaatgcctcct-3' and 5'-tgtggtcatgagtccttcca-
3') expression, a commonly used housekeeping gene.
RNA preparation and miRNA real-time PCR
Total RNA was isolated using the mirVana miRNA iso-
lation kit (Ambion). miRNA analysis was performed using
RT2 miRNA PCR Arrays (Qiagen) and individual miRNA
expression were independently quantified using the
TaqMan MicroRNA (Applied Biosystems), according to
the manufacturer’s protocols.
Production of lentiviral particles
The hsa-miR-488 and Negative Control lentivirus was
transfected with 3rd generation packaging mix from Ap-
plied Biological Materials Inc. (ABM) into human 293FT
cells using Lentifectin(ABM) in Opti-MEM I medium
(Invitrogen, CA) and cultured overnight. The super-
natant was collected and lentiviral particles were con-
centrated using Lenti-X Concentrator (Clontech, CA).
Experimental OA and histology of OA cartilage
Experimental OA was induced by destabilization of the
medial meniscus (DMM) surgery 8-week-old male mice.
Sham-operated animals injected with empty lentiviruses
(mock transduction) were used as controls for DMM.
Mice were killed 8 weeks after DMM surgery or 2 weeks
after intraarticular injection (1 × 109 plaque-forming
units (PFU)) of si-ZIP-8-expressing lentiviruses for histo-
logical and biochemical analyses. Cartilage destruction
in mice was examined using Safranin O staining. Briefly,
knee joints were fixed in 4% paraformaldehyde, decal-
cified in 0.5 M EDTA (pH 7.4) for 14 days at 4 °C, and
embedded in paraffin. The paraffin blocks were sec-
tioned at 6 μm thickness. The sections were deparaffinized
in xylene, hydrated with graded ethanol, and stained with
Safranin O.
Actin staining
Cells grown on coverslips were washed three times with
phosphate-buffered saline (PBS) and then fixed with 4%
paraformaldehyde in PBS for 10 min, washed three times
with PBS, permeabilized with 0.1% Triton X-100 in PBS
for 5 min at room temperature. After washing three
times in PBS, cells were blocked with 1% bovine serum
albumin (BSA) for 1 h at room temperature. Incubation
with Alexa fluor 488-conjugated phalloidin (Invitrogen)
was performed in blocking solution (1% BSA in PBS) for
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were stained with 4,6-diamidino-2-phenylindole (DAPI,
Santa Cruz Biotechnologies). Samples were mounted in
mounting medium (Biomedia).
Results and discussion
As previously mentioned, miRNA has been shown to in-
volve in various pathological conditions [18-23]. To
identify miRNA involved in osteoarthritic conditions, 10
osteoarthritic (OA) cartilages were obtained from pa-
tients diagnosed with OA according to the American
College of Rheumatology (ACR) criteria, which under-
went joint surgery and 5 normal cartilages were obtained
from biopsy sample of normal patients. OA cartilage was
confirmed by a degenerative morphology with OA pro-
gression and staining with Safranin O (Figure 1A). Articu-
lar chondrocytes were isolated, cultured, and the
expression levels of miRNAs using RT2 miRNA PCR Ar-
rays kit. Among miRNA analyzed, miR-23b, miR-30d,
miR-132, miR-140-3p, miR-145, miR-150, miR-204 were
up-regulated in OA chondrocytes whereas miR-22,
miR-25, miR-26, miR-30c, miR-92b, miR-127, miR-194,
miR-197, miR-296-5p, miR-342-3p, miR-488 were down-
regulated in OA chondrocytes (Figure 1B). Particularly,
miR-488 was decreased more than 60% in OA chondro-
cytes compared to normal chondrocytes suggesting its
positive role in articular chondrocytes.
The processing of precursor (pre) miR 488* stem-loop
produces two mature miRNAs, namely miR 488* and
miR 488. Pre miR 488 was almost 90% conserved among
human, mouse, rat, cow and horse genomes and the ma-
ture miR 488 was found to be 95% conserved overall
and 100% identical in the seed region. However, the ex-
pression of miR-488 in normal human tissues and dis-
ease states has not been extensively studied. To validate
the role of miR-488 in human articular chondrocytes,
chondrocytes isolated from biopsy cartilage of normal






































Figure 1 Expression profile of miRNAs in OA chondrocytes. (A) Images
panel) and safranin O staining of OA cartilage (lower panel). (B) Changes in
from control cells (P < 0.005).treated with IL-1β displayed degenerative characteristics,
i.e. degenerative morphology, inhibited cytoskeletal
reorganization as assayed by phalloidin staining, sup-
pressed level of type II collagen RNA as assayed by real-
time PCR. However, this degenerative characteristics
induced by IL-1β was recovered by co-introduction of
miR-488 precursor (Figure 2A). Most significant degener-
ation was occurred with co-induction of miR-488 inhibi-
tor. Furthermore, exposure of cells to IL-1β, a factor
induced degeneration of articular chondrocytes [24] as
confirmed by suppression of type II collagen level, down-
regulated miR-488 level whereas exposure of cells to
TGF-β3, a factor induced differentiation/proliferation of
articular chondrocytes [25,26] as confirmed by stimula-
tion of type II collagen level, up-regulated miR-488 level
(Figure 2B).
Proteolytic degradation of cartilage by matrix-degrading
enzymes such as collagenase 3 (matrix metalloproteinase
13, MMP-13) is a hallmark of osteoarthritis (OA). It has
been shown that IL-1β induced MMP-13 during cartilage
degradation in OA joints [27]. Consistent with previous
reports, the RNA level MMP-13 was increased with IL-1β
treatment in a dose dependant manner (Figure 1A left
panel). Treatment of 10 ng/ml IL-1β increased the MMP-
13 RNA level in a time dependant manner and also in-
duced protein and activation level of MMP-13 (Figure 1A
right panel).
Several recent studies demonstrate the correlation be-
tween miRNAs and MMP-13 in human OA chondrocytes
[28-31]. It has been known that miR-140 [28] and miR-27
[30] negatively regulates MMP-13 expression indirectly by
modulating NF-κB signaling or targeting BMP-7 and miR-
27b binds directly with the 3’UTR of human MMP-13
mRNA [31]. In this study, miR-488 did not directly bind
to 3’ UTR of MMP-13 in articular chondrocytes (data not
shown) suggesting indirect regulation of MMP-13 by
miR-488. Since Zn2+ is required for catalytic activity of











































































of human articular chondrocytes isolated form OA cartilages (upper






























































Figure 2 MiR-488 is involved in degeneration of human articular chondrocytes. (A) Human articular chondrocytes isolated from biopsy
normal cartilage were treated with 10 ng/ml IL-1β in the presence of miR-488 or miR-488 inhibitor (anti-miR-488), stained with phalloidin (left
panel), and expression level of type II collagen was analyzed (right panel). (B) Human articular chondrocytes isolated from biopsy normal cartilage
were treated with 10 ng/ml IL-1β or 5 ng/ml TGF-β3, stained with phalloidin (left panel), and expression level of type II collagen and miR-488
were analyzed by real-time PCR (right panel). *, statistically different from control cells (p < 0.001). The error bars represent average of data from
each human sample.
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of Zn2+ concentration. Zn2+ concentrations are high in
bone, cartilage, and teeth and bone growth retardation has
been reported in Zn2+-deficient conditions [33] indicating
Zn2+ may play a role in bone/cartilage metabolism.
Homeostasis of Zn2+ is tightly controlled by two major
families of Zn transporters, Zn importers (SLC39s/ZIPs)
and exporters (SLC30s/ZnTs) [34]. Among the ZIP family
of metal-ion transporters, ZIP-2, ZIP-6, ZIP-7, and ZIP-8
was increased with exposure of human articular chondro-
cyte to IL-1β and ZIP-2, ZIP-7, and ZIP-8 were decreased
with exposure of cells to TGF-β3 (Figure 3B). ZIP-2, ZIP-
7 and ZIP-8 were conversely regulated by IL-1β and TGF-
β3. Particularly, ZIP-8 showed 300% increase by IL-1β and
90% decrease by TGF-β3. Previous report [35] showed
that type X collagen, a marker for hypertrophic chondro-
cytes, was decreased and defected in the maturation of
chondrocytes in Slc39a13-KO mice.
We next asked if the observed induction of MMP-13
activity by IL-1β is due to the modulation and interaction
of miR488 to ZIP. Among ZIP-2, -7, -8 whose inductions
were reversely regulated by IL-1β and TGF-β3, increased
level of ZIP-8 by IL-1β inhibited with co-introduction of
miR-488. And most significant increase in ZIP-8 induction
was occurred when cells were exposed to miR-488 inhibi-
tor with IL-1β (Figure 3C). To address the direct inter-
action between miR-488 and ZIP-8, we cloned a segmentof ZIP-8 3’UTR (NM_001135147.1, 1700bp ~ 4098bp), co-
transfected with miR-488 or negative control in human ar-
ticular chondrocytes, and luciferase activity was measured
after 48 hr. As seen in Figure 3D, miR-488 reduced lucifer-
ase activity of the ZIP-8 3’ UTR construct by about 30% as
compared to that with the negative control. To investigate
the expression level of ZIP-8 during pathogenesis, OA
chondrocytes were isolated OA cartilage obtained from
patient who undertaken total knee replacement (Figure 3D
insert). The protein level of ZIP-8 was dramatically in-
creased in OA chondrocytes compared to normal
chondrocytes. Normal chondrocytes were isolated from
biopsy tissue of normal patients.
Furthermore, the protein level of ZIP-8 was increased
in OA chondrocytes compared to normal chondrocytes
suggesting the negative role of ZIP-8 during OA patho-
genesis (Figure 3D). In OA chondrocytes, the expression
level of type II collagen was recovered by the knock-
down of ZIP-8 (Figure 4A). In opposition, MMP-13 acti-
vation was decreased by the knockdown of ZIP-8.
Furthermore, to validate the role of ZIP-8 in cartilage
destruction in vivo, we suppressed ZIP-8 in cartilage tis-
sue by injecting siZIP-8-expressing lentiviruses into
DMM mouse knee joints (Figure 4B). Cartilage destruc-
tion caused by DMM surgery was significantly reduced
with down-regulation of ZIP-8 suggesting its protective
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Figure 3 MiR-488 targets ZIP8. Human articular chondrocytes isolated from biopsy normal cartilage were isolated as described in
Material and Method. (A) Articular chondrocytes were treated 2.5, 5, or 10 ng/ml IL-1β and expression level of MMP-13 was examined by real-
time PCR (left panel). Cells were treated with 10 ng/ml of IL-1β, expression level was analyzed at indicated time points by real-time PCR (right
upper panel), and activation of MMP-13 was analyzed and zymography (Zymo, right lower panel) and immunoblotting (IB, right lower panel),
respectively. (B) Expression levels of ZIPs were analyzed by real-time PCR. (C) Human articular chondrocytes isolated from biopsy normal cartilage
were treated with 10 ng/ml IL-1β in the presence of miR-488 or miR-488 inhibitor (anti-miR-488) and expression levels of ZIP2, -7, -8 were examined by
real-time PCR. (D) Luciferase reporter gene assays of cells expressing the construct containing the human ZIP2, -7, -8 3’-UTR in the absence or presence
of miR-488. The expression level of ZIP-8 was analyzed by immunoblotting in normal and OA chondrocytes.




















Figure 4 Suppression of ZIP8 protects DMM-induced cartilage degradation. (A) OA chondrocytes were infected with si-ZIP-8 virus and the
expression level of MMP-13, type II collagen was examined by immunoblotting. (B) Mouse cartilages with OA induced by destabilization of the
medial meniscus (DMM) were stained with Safranin O. Sham-operated (Sham) cartilage was used as control.
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In sum, our data suggest that miR-488 act as a protective
role for chondrocyte differentiation/cartilage development
by inhibiting MMP-13 activity through targeting ZIP-8.
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